<DOC>
	<DOCNO>NCT01220388</DOCNO>
	<brief_summary>Data literature previous vitro research conduct investigator ' laboratory ( INSERM U413/EA4310 , University Rouen ) suggest adrenal corticosteroid secretion might control paracrine mechanism involve serotonin type IV receptor ( 5-HT 4 ) . L-lysine , common amino-acid show act 5-HT4 agonist vitro well vivo . In present physiology trial , plasma aldosterone cortisol level measure treatment aprepitant versus placebo , basal condition activation adrenocortical function various stimulus , include upright posture , metoclopramide , 3 day salt-free diet . All healthy volunteer give two substance ( L-lysine placebo ) random order two 13 day period separate 14 day-wash-out . This study allow determine role 5-HT4 receptor control corticosteroid production normal man .</brief_summary>
	<brief_title>Effects L-lysine Adrenal Secretion</brief_title>
	<detailed_description>STUDY DESIGN Proof concept , interventional , monocentric , randomise , double blind , cross-over study : The effect L-lysine corticosteroid secretion compare placebo . STUDY OBJECTIVES Main objective : verify adrenal corticosteroid secretion actually control L-lysine . Secondary objective : determine physiological condition involve control adrenocortical function t5-HT4 receptor . NUMBER OF SUBJECTS 20 healthy volunteer ELIGIBILITY CRITERIA ( see ) DURATION OF STUDY Overall duration : 13 month Inclusion period : 12 month Follow period ( 1 subject ) : 5 week Exclusion period : 1 month ENDPOINTS PRIMARY ENDPOINT : blood aldosterone variation orthostatic test SECONDARY ENDPOINTS Basal aldosterone alteration Aldosterone variation metoclopramide &amp; salt-free diet test Basal stimulate ( 3 different test ) alteration renin , cortisol &amp; ACTH REGULATORY AUTHORIZATIONS Ethics committee authorization : jan 21,2010 Regulatory authorization : july 9th 2010</detailed_description>
	<criteria>Male subject ; Age range 18 45 year old ; Submitted social security regimen ; Agreeing study &amp; Informed consent form sign ; Body mass index ( [ weight ( kg ) /height ( ) ] Â² ) &lt; 27 ; No treatment receive 6 week inclusion ; No anomaly : complete clinical examination , pulse measurement , ECG ; Blood pressure AMBP : Mean systolic blood pressure &lt; 135 mmHg &amp; Mean diastolic blood pressure &lt; 85 mmHg No biological abnormality biological test No participation clinical trial 3 month inclusion . Subject agree study impossible followup ; Known history significant medical surgical pathology , notably endocrine ; Renal hepatic insufficiency ; Nephrotic syndrome ; Edematous syndrome ; Hypertension postural hypotension ; Cardiac rhythm conduction pathology ; Cardiac insufficiency ; Epilepsy ; Significant psychiatric disorder ; Known history severe allergy , hypersensitivity metoclopramide ; Hereditary problem fructose intolerance , glucosegalactose malabsorption sucraseisomaltase deficit ; Impaired lactose tolerance .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Aldosterone</keyword>
	<keyword>L-lysine</keyword>
	<keyword>Cortisol</keyword>
	<keyword>Adrenal gland</keyword>
</DOC>